Year: 2021

Victory Square Technologies Reports Nine Months Ended September 30, 2021

Written by Customer Service on November 30, 2021. Posted in Earnings Releases And Operating Results.

“2021 has been a year of continued growth and new opportunities for Victory Square. Q3 2021 was another strong quarter in which we achieved a seventh consecutive quarter with positive comprehensive income, issued a share dividend, and successfully listed Fantasy 360 Technologies Inc. (CSE:VRAR). Our balance sheet has never been stronger and our team is laser focused on unlocking value from the existing portfolio, and building a pipeline of new opportunities through strategic investment and acquisitions.” – Shafin Diamond Tejani, Chief Executive Officer of Victory Square. VANCOUVER, British Columbia, Nov. 29, 2021 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square” or “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that provides investors access to a diverse portfolio of next generation technology companies...

Tinley’s Announces Q3 2021 Results and Provides Corporate Updates

Written by Customer Service on November 30, 2021. Posted in Earnings Releases And Operating Results.

TORONTO and LOS ANGELES, Nov. 29, 2021 (GLOBE NEWSWIRE) — The Tinley Beverage Company Inc. (CSE:TNY; OTC:TNYBF) (“Tinley’s” or the “Company”) is pleased to provide corporate updates to coincide with the release today of the Company’s condensed interim consolidated financial statements and management’s discussion and analysis thereon for the three and nine months ended September 30, 2021, which are accessible under the Company’s profile on SEDAR at www.sedar.com. Third Quarter 2021 Financial Highlights The following information compares certain financial results of the Company for the three months ended September 30, 2021 against the same period in 2020:Sales of $198,165 in 2021, compared to $34,628 in 2020, representing an increase of 472%; Gross margin profit of $28,234 in 2021, compared to a gross margin loss of $65,795 in...

Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China

Written by Customer Service on November 30, 2021. Posted in Public Companies.

Collaboration highlights the value of MRD solid tumor data generated by Genetron’s Mutation Capsule platform, and further accelerates product development BEIJING, Nov. 30, 2021 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collaboration agreement with AstraZeneca R&D China (“AstraZeneca – LSE/STO/Nasdaq: AZN”) for the joint development in China of next-generation sequencing (NGS)-based tumor-informed (personalized) minimal residual disease (MRD) tests for various solid tumor types. AstraZeneca plans to incorporate the co-developed tests for China-specific studies. Under...

BIGG Digital Assets Inc. Reports Financial Results For Third Quarter 2021

Written by Customer Service on November 30, 2021. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, Nov. 29, 2021 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”)(CSE: BIGG; OTCQX: BBKCF; WKN: A2PS9W), owner of Netcoins (Netcoins.ca) (“Netcoins”), the online cryptocurrency brokerage that makes it easy for Canadians to buy, sell, and understand cryptocurrency, and Blockchain Intelligence Group (blockchaingroup.io) (“BIG”), a leading developer of blockchain technology search, risk-scoring and data analytics solutions, is pleased to report its fiscal Q3 2021 financial results for the three and nine months ended September 30, 2021. All figures are in Canadian Dollars (CAD) unless otherwise stated. Q3 2021 Highlights:Gross operating revenue of $2.625M (up 308% YoY), with $2.198M for Netcoins and $427k for Blockchain Intelligence Group (“BIG”) Netcoins revenue for Q3 represents 462%...

Monument Reports First Quarter Fiscal 2022 (“Q1 FY2022”) Results

Written by Customer Service on November 30, 2021. Posted in Earnings Releases And Operating Results.

Gross Revenue of $2.38 Million and Cash Cost of US$1,430/Oz VANCOUVER, British Columbia, Nov. 29, 2021 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its first quarter of fiscal 2022 production and financial results for the three months ended September 30, 2021. All amounts are expressed in United States dollars (“US$”) unless otherwise indicated (refer to www.sedar.com for full financial results). President and CEO Cathy Zhai commented, “2022 fiscal year is full of challenge and would be rewarding for Monument when the Company stays focused on execution of the corporate strategies. During the quarter, the Selinsing flotation plant construction was kicked off with engineering design near completion, long lead items procured, and the earthworks at site reached 90%...

Captor Capital Releases Unaudited Condensed Interim Consolidated Financial Statements For Quarter Ended September 30, 2021

Written by Customer Service on November 30, 2021. Posted in Public Companies.

Records Continuous Revenue Growth TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR; FRANKFURT: NMVA; STUTTGART: NMVA), (“Captor” or the “Company”), is pleased to announce today the release of its Unaudited Condensed Interim Consolidated Financial Statements and MD&A for the three and six months ended September 30, 2021. In the six-month period, revenues from the sale of cannabis at the Company’s California dispensary network were $15,235,733, with the Company recording a gross profit of $5,179,829. Management Commentary “We have seen significant growth quarter-over-quarter, as Captor continues to benefit from the geographic location and retail footprint of its dispensaries, and our highly trained staff,” said Captor Capital CEO, John Zorbas. “The retail locations are well-positioned...

Denarius Announces Third Quarter and First Nine Months 2021 Results

Written by Customer Service on November 30, 2021. Posted in Earnings Releases And Operating Results.

TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) — Denarius Silver Corp. (“Denarius” or “the Company”) (TSXV: DSLV) announced today that it has filed its unaudited interim condensed consolidated financial statements and accompanying management’s discussion and analysis (MD&A) for the three and nine months ended September 30, 2021. These documents can be found on its website at www.denariussilver.com and by reviewing its profile on SEDAR at www.sedar.com. All financial figures contained herein are expressed in U.S. dollars unless otherwise noted. Third Quarter and First Nine Months 2021 HighlightsDenarius is a junior exploration company currently drilling its Lomero-Poyatos polymetallic deposit located on the Spanish side of the prolific copper rich Iberian Pyrite Belt. The Company also commenced drilling its Guia Antigua silver-gold...

Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

Written by Customer Service on November 30, 2021. Posted in Public Companies.

4th approved indication for toripalimab SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the National Medical Products Administration (NMPA) of China has approved its supplemental New Drug Application (sNDA) for toripalimab in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma (the “NPC”). This is the fourth approved indication for toripalimab in China. In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal...

Amarillo to be acquired by Hochschild

Written by Customer Service on November 30, 2021. Posted in Mergers And Acquisitions.

TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) — Amarillo Gold Corporation (“Amarillo” or the “Company”) (TSXV: AGC, OTCQB: AGCBF) has entered into an agreement (the “Arrangement Agreement”) with Hochschild Mining PLC (“Hochschild”), whereby Hochschild will acquire all of the outstanding shares of Amarillo by way of a plan of arrangement (the “Arrangement”) under the Business Corporations Act (British Columbia). Pursuant to the Arrangement, each share of Amarillo will be exchanged for cash consideration of C$0.40 and one share of a new Brazil-focused exploration company, Lavras Gold Corp. (“Lavras SpinCo”), based in Toronto, Ontario. Lavras SpinCo will be capitalized with C$10 million cash and will hold all assets and rights with respect the Lavras do Sul gold project (the “Lavras Project”) located in southern Brazil in the state of Rio...

Wesana Health Reports Q3 2021 Financial Results

Written by Customer Service on November 30, 2021. Posted in Earnings Releases And Operating Results.

CHICAGO and TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven life sciences company, has announced its quarterly financial results for the three- and nine-month period ending September 30, 2021. Q3 2021 HighlightsEnded the third quarter with US$11,266,187 in cash Completed the acquisition of PsyTech and related transactions, launching Care Delivery as a new business segment consisting of Wesana Solutions, Wesana Clinics and PsyTech Connect Committed US$1.5mm in funding to Multidisciplinary Association for Psychedelic Studies (“MAPS”) to work towards developing a partnership agreement on the research of the application of MAPS’ psychedelic-assisted therapy programs towards the treatment of Traumatic Brain Injury (“TBI”) Wesana was included...

Year: 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals